MedRx Co., Ltd
Notice of patent allowance for Bondlido (U.S.)
通知 of U.S. patent allowance for Bondlido. The manufacturing process technology ensuring uniformity and stability of a formulation for treating postherpetic neuralgia (PHN) is protected. The patent term extends to 2040. Considered to contribute to medium- to long-term performance improvement. However, no impact on current period earnings forecast.
Key Figures
- Bondlido: U.S. patent allowance (valid until 2040)
- Geographic rights in the patent family: Japan, India, Canada, Australia, South Korea, Russia, South Africa, Mexico
- Market size estimate: U.S. lidocaine patch market about 44 billion yen (295 million USD, IQVIA)
AI要約
Overview
This is an announcement of the U.S. patent allowance for Bondlido, reporting progress of a patent family that protects the manufacturing process technology for lidocaine-containing patches as a treatment for postherpetic neuralgia. The patent is valid in the U.S. until 2040, and has been granted in Japan, India, Canada, Australia, South Korea, Russia, South Africa, and Mexico, with pursuit of rights in other regions as well. There is no change to the current period's earnings forecast as a financial impact.
Business Implications and Outlook
Bondlido is a lidocaine patch product with U.S. regulatory approval, which is expected to offer reduced skin irritation, superior adhesion, and better adhesion during movement compared with Lidoderm. The U.S. lidocaine patch market is estimated at around 44 billion yen, and in the medium to long term could facilitate greater market penetration. The short-term impact on earnings is limited, but the long-term outlook is expected to support earnings growth.
Medirex Co., Ltd.
Company overview · Stock price · Financial data · All IR
